A Phase I Study of the PI3-Kinase Inhibitor BKM120 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors

Trial Profile

A Phase I Study of the PI3-Kinase Inhibitor BKM120 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 18 Aug 2015

At a glance

  • Drugs Buparlisib (Primary) ; Cisplatin; Gemcitabine
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Aug 2015 Planned initiation date changed from 1 Jun 2015 to 1 Sep 2015.
    • 12 Aug 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top